A current perspective on stereotactic body radiation therapy for pancreatic cancer

References

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• VincentAHermanJSchulickRHrubanRHGogginsMPancreatic cancerLancet2011378979160762021620466
   PubMed Web of Science ®Google Scholar
• OettleHPostSNeuhausPAdjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trialJAMA2007297326727717227978
   PubMed Web of Science ®Google Scholar
• KalserMHEllenbergSSPancreatic cancer. adjuvant combined radiation and chemotherapy following curative resectionArch Surg198512088999034015380
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPStockenDDBassiCAdjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJAMA2010304101073108120823433
   PubMed Web of Science ®Google Scholar
• HuguetFAndréTHammelPImpact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studiesJ Clin Oncol200725332633117235048
   PubMed Web of Science ®Google Scholar
• HammelPHuguetFvan LaethemJ-LEffect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trialJAMA2016315171844185327139057
   PubMed Web of Science ®Google Scholar
• Iacobuzio-DonahueCAFuBYachidaSDPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancerJ Clin Oncol200927111806181319273710
   PubMed Web of Science ®Google Scholar
• LeeMTKimJJDinniwellRPhase I study of individualized stereotactic body radiotherapy of liver metastasesJ Clin Oncol200927101585159119255313
   PubMed Web of Science ®Google Scholar
• KoongACLeQTHoAPhase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancerInt J Radiat Oncol Biol Phys20045841017102115001240
   PubMed Web of Science ®Google Scholar
• KoongACChristoffersonELeQ-TPhase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancerInt J Radiat Oncol Biol Phys200563232032316168826
   PubMed Web of Science ®Google Scholar
• SchellenbergDGoodmanKALeeFGemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancerInt J Radiat Oncol Biol Phys200872367868618395362
   PubMed Web of Science ®Google Scholar
• SchellenbergDKimJChristman-SkiellerCSingle-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancerInt J Radiat Oncol Biol Phys201181118118821549517
   PubMed Web of Science ®Google Scholar
• de LangeSMvan GroeningenCJMeijerOWMGemcitabine-radiotherapy in patients with locally advanced pancreatic cancerEur J Cancer20023891212121712044508
   PubMed Web of Science ®Google Scholar
• WillettCGDel CastilloCFShihHALong-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancerAnn Surg2005241229529915650640
   PubMed Web of Science ®Google Scholar
• HøyerMRoedHSengelovLPhase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinomaRadiother Oncol2005761485315990186
   PubMed Web of Science ®Google Scholar
• PolistinaFCostantinGCasamassimaFUnresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical explorationAnn Surg Oncol20101782092210120224860
   PubMed Web of Science ®Google Scholar
• GurkaMKCollinsSPSlackRStereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safetyRadiat Oncol2013814423452509
   PubMed Web of Science ®Google Scholar
• HermanJMChangDTGoodmanKAPhase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinomaCancer201512171128113725538019
   PubMed Web of Science ®Google Scholar
• MoningiSMarciscanoAERosatiLMStereotactic body radiation therapy in pancreatic cancer: the new frontierExpert Rev Anticancer Ther201414121461147525183386
   PubMed Web of Science ®Google Scholar
• HongTSRyanDPBlaszkowskyLSPhase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the headInt J Radiat Oncol Biol Phys201179115115720421151
   PubMed Web of Science ®Google Scholar
• HongTSRyanDPBorgerDRA phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinomaInt J Radiat Oncol Biol Phys201489483083824867540
   PubMed Web of Science ®Google Scholar
• AssifiMMLuXEiblGReberHALiGHinesOJNeoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trialsSurgery2011150346647321878232
   PubMed Web of Science ®Google Scholar
• RajagopalanMSHeronDEWegnerREPathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancerRadiat Oncol20138125424175982
   PubMed Web of Science ®Google Scholar
• MellonEAHoffeSESpringettGMLong-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinomaActa Oncol201554797998525734581
   PubMed Web of Science ®Google Scholar
• MoningiSDholakiaASRamanSPThe role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experienceAnn Surg Oncol20152272352235825564157
   PubMed Web of Science ®Google Scholar
• RwigemaJ-CMHeronDEParikhSDAdjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive marginsJ Gastrointest Cancer2012431707620809393
   PubMedGoogle Scholar
• JayachandranPMinnAYVan DamJNortonJAKoongACChangDTInterfractional uncertainty in the treatment of pancreatic cancer with radiationInt J Radiat Oncol Biol Phys201076260360719879062
   PubMed Web of Science ®Google Scholar
• TaniguchiCMMurphyJDEclovNDosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancerInt J Radiat Oncol Biol Phys20138541090109523273994
   PubMed Web of Science ®Google Scholar
• SchellenbergDQuonAMinnAY18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapyInt J Radiat Oncol Biol Phys20107751420142520056345
   PubMed Web of Science ®Google Scholar
• DholakiaASChaudhryMLealJPBaseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapyInt J Radiat Oncol Biol Phys201489353954624751410
   PubMed Web of Science ®Google Scholar
• FletcherJGWiersemaMJFarrellMAPancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CTRadiology20032291819014519871
   PubMed Web of Science ®Google Scholar
• ScorsettiMAlongiFCastiglioniSFeasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatmentsRadiat Oncol20116111321910868
   PubMed Web of Science ®Google Scholar
• AlagappanMPollomELvon EybenRAlbumin and neutrophil-lymphocyte ratio (NLR) predict survival in patients with pancreatic adenocarcinoma treated with SBRTAm J Clin Oncol2016 Epub2016111
   Web of Science ®Google Scholar
• JavleMLiYTanDBiomarkers of TGF-β signaling pathway and prognosis of pancreatic cancerPLoS One201491e8594224465802
   PubMed Web of Science ®Google Scholar
• Radiation Therapy Oncology GroupHigh or Standard Intensity Radiation Therapy after Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients with Pancreatic Cancer That Cannot Be Removed by Surgery Available from: https://clinicaltrials.gov/ct2/show/NCT01921751. NCT01921751Accessed May 23, 2016
   Google Scholar
• University of RochesterPilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer Available from: https://clinicaltrials.gov/ct2/show/NCT02347618. NCT02347618Accessed May 23, 2016
   Google Scholar
• University of PittsburghRadiosurgery for Resected Pancreas Available from: https://clinicaltrials.gov/ct2/show/NCT01357525. NCT01357525Accessed May 23, 2016
   Google Scholar
• University of MarylandBorderline Pancreas Study: FOLFIRINOX +SBRT (GCC 1324) Available from: https://clinicaltrials.gov/ct2/show/NCT01992705. NCT01992705Accessed May 23, 2016
   Google Scholar
• Emory UniversityPhase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer Available from: https://clinicaltrials.gov/ct2/show/NCT01446458. NCT01446458Accessed May 23, 2016
   Google Scholar
• Duke UniversityGemcitabine/Nab-Paclitaxel with HIGRT in Resectable Pancreatic Cancer Available from: https://clinicaltrials.gov/ct2/show/NCT02318095. NCT02318095Accessed May 23, 2016
   Google Scholar
• LutzEYeoCJLillemoeKDA lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activationAnn Surg2011253232833521217520
   PubMed Web of Science ®Google Scholar
• LaheruDLutzEBurkeJAllogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activationClin Cancer Res20081451455146318316569
   PubMed Web of Science ®Google Scholar
• NewLink Genetics CorporationImmunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer Available from: https://clinicaltrials.gov/ct2/show/NCT02405585. NCT02405585Accessed May 23, 2016
   Google Scholar
• FinkelsteinSETimmermanRMcBrideWHThe confluence of stereotactic ablative radiotherapy and tumor immunologyClin Dev Immunol2011201143975222162711
   PubMedGoogle Scholar
• TozziAComitoTAlongiFSBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experienceRadiat Oncol20138114823799996
   PubMed Web of Science ®Google Scholar